Theratechnologies (NASDAQ:THTX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Theratechnologies (NASDAQ:THTX) posted its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03), Fidelity Earnings reports. Theratechnologies had a negative net margin of 37.10% and a negative return on equity of 112.84%. During the same quarter in the prior year, the firm posted ($0.09) earnings per share.

Shares of THTX stock traded down $0.02 during trading hours on Thursday, reaching $3.55. The stock had a trading volume of 3,582 shares, compared to its average volume of 310,056. The stock’s fifty day simple moving average is $3.61 and its 200 day simple moving average is $3.63. The firm has a market capitalization of $336.23 million, a PE ratio of -11.90 and a beta of 1.65. The company has a current ratio of 2.41, a quick ratio of 1.74 and a debt-to-equity ratio of 1.52. Theratechnologies has a 12 month low of $1.83 and a 12 month high of $4.46.

A number of research firms recently commented on THTX. Canaccord Genuity cut shares of Theratechnologies from a “buy” rating to a “hold” rating and lowered their price objective for the company from $8.00 to $3.00 in a research report on Thursday, July 29th. Zacks Investment Research raised shares of Theratechnologies from a “sell” rating to a “hold” rating in a research report on Wednesday, September 15th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Theratechnologies currently has a consensus rating of “Hold” and a consensus target price of $3.17.

A hedge fund recently raised its stake in Theratechnologies stock. Morgan Stanley lifted its position in shares of Theratechnologies Inc. (NASDAQ:THTX) by 143.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,716,512 shares of the company’s stock after purchasing an additional 1,012,777 shares during the quarter. Morgan Stanley owned about 1.81% of Theratechnologies worth $6,660,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 19.29% of the company’s stock.

About Theratechnologies

Theratechnologies, Inc is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Further Reading: How to read a candlestick chart

Earnings History for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.